ADK Diagnos Inc

DIAGNOS inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in the early detection of serious health issues thanks to its artificial intelligence technology, FLAIRE, adds a second site to screen patients in the ophthalmology department at the Centre Hospitalier de l’Université de Montréal (CHUM) for the automated diabetic retinopathy screening clinic assisted by AI (Artificial Intelligence).

To further its collaboration with the ophthalmology department, DIAGNOS is installing a second site in that department. The objective is to continue to improve the screening process with patients posing more challenging conditions.

AI for detection and triageOur early detection service includes an automated AI analysis of fundus imagery together with a triage system according to the degree of severity. This proprietary service is only available via our CARA telehealth platform (Computer Assisted Retina Analysis).

Improving patient servicesThe DIAGNOS automated screening solution significantly increases accessibility for diabetic and hypertensive patients subject to annual screening. Screening is done at the service centre using fundus photography. The process is fast, painless, and very simple for the patient. The CARA platform will facilitate identification and expedited triage of patients suffering from retinopathies who have been referred to the ophthalmology department following a consultation at the endocrinology or diabetes clinic.

About DIAGNOSDIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.